Anti-Interleukin-1 in Diabetes Action (AIDA)

This study has been completed.
Sponsor:
Collaborators:
Juvenile Diabetes Research Foundation
Oeresund Diabetes Academy
Information provided by (Responsible Party):
Lise Tarnow, Steno Diabetes Center
ClinicalTrials.gov Identifier:
NCT00711503
First received: July 3, 2008
Last updated: August 31, 2012
Last verified: August 2012

July 3, 2008
August 31, 2012
January 2009
January 2012   (final data collection date for primary outcome measure)
Δ 2-h AUC C-peptide response [ Time Frame: 1 month, 3 months, 6 months, 9 months ] [ Designated as safety issue: No ]
Δ 2-h AUC C-peptide response [ Time Frame: every study visit ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00711503 on ClinicalTrials.gov Archive Site
Incremental and/or peak C-peptide response, Time to peak C-peptide, insulin requirement per kg body weight per day,frequency of insulin free state with maintenance of HbA1c <7.5%, HbA1c, Means of fasting glucose values, circulating IL-6 and CRP [ Time Frame: 1 month, 3 months, 6 months, 9 months ] [ Designated as safety issue: No ]
Incremental and/or peak C-peptide response, Time to peak C-peptide, insulin requirement per kg body weight per day,frequency of insulin free state with maintenance of HbA1c <7.5%, HbA1c, Means of fasting glucose values, circulating IL-6 and CRP [ Time Frame: every study visit ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Anti-Interleukin-1 in Diabetes Action
A Randomised Clinical Trial of the Effect of Interleukin-1 Receptor Antagonism on the Insulin Production in Patients With New Onset Type 1 Diabetes

A draw trial of the effect of Interleukin-1 Receptor Antagonist (anakinra, Kineret®) on the insulin production in patients with new onset Type 1 diabetes.

Kineret® is already being used in the treatment of patients suffering from rheumatoid arthritis and preclinical studies are now suggesting that it may also be useful for patients with Type 1 diabetes. The active substance in Kineret is interleukin-1 receptor antagonist, a blocker of an immune-signal molecule named interleukin-1.

The trial is a blinded randomised trial, in which the patient is allocated to receive the active drug (Kineret®) or placebo (saline). The hypothesis is that anti-IL-1 treatment as add-on therapy to conventional insulin therapy will preserve or enhance beta-cell function.

Objectives:

The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new onset Type 1 diabetes.

Trial Design:

A randomized, placebo controlled, double masked, parallel group, multicentre trial of IL-1 antagonism in subjects with newly-diagnosed Type 1 diabetes. Patients are instructed to inject 100 mg human recombinant interleukin-1 receptor antagonist (anakinra, Kineret®, Amgen, CA) or placebo s.c. once daily for 2 years. Endpoints will be evaluated every three months, with an interim analysis after 6 months.

Trial population:

The design will be a two-stage phase 2a study to address feasibility, safety/tolerability and potential efficacy. In the first phase 80 patients between 18 and 35 years of age with new on-set Type 1 diabetes will be randomized to anakinra or placebo, and endpoints will be analyzed as an interim analysis after 6 months by an independent data and safety monitoring board (DSMB). A futility analysis will be performed at this time point to prevent continuation of the trial if it shows no likelihood of demonstrating efficacy. In the event the trial does show promise of efficacy considering the power of the first phase based on a conditional analysis the DSMB can recommend prolongation of the study with recruitment to ensure adequate power, and that additional funding is provided.

Methods and interventions:

The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (anakinra) at a dose of 100 mg once daily or placebo by subcutaneous injection at the same time-point in the morning. Primary and secondary endpoints and safety parameters are investigated after 1 month and then every 3 months.

Safety:

Anakinra is FDA approved for the indication rheumatoid arthritis and has an acceptable risk / benefit profile in this indication, with more than 100.000 patients treated. Most common ad-verse events include mild and transient local injection reactions in 20-50% of subjects treated with Anakinra. Consistent with its mechanism of action, anakinra reduces WBC/ANC in 2.4% of patients and this may increase the risk of infection. Accordingly, treatment with anakinra will not be initiated in patients with active infections. Safety will be monitored by physical exams and blood and urine tests.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Type 1 Diabetes
  • Drug: anakinra
    The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
    Other Name: Kineret
  • Drug: saline
    The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
    Other Name: saline
  • Placebo Comparator: 2
    The patients are instructed to administer placebo by subcutaneous injection
    Intervention: Drug: saline
  • Experimental: 1
    The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
    Intervention: Drug: anakinra

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
69
June 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 1 diabetes diagnosed according to WHO 1999 criteria
  • Positive GAD auto-antibodies
  • Age 18-35 yrs at onset of diabetes
  • Time from first symptoms of diabetes < 12 weeks
  • Peak C-peptide more than or equal to 200 pM after a standardized mixed meal test (Boost) at a test carried out when the subject is metabolically stable, i.e. after resolution of any polyuria, polydypsia or ketoacidosis.

Exclusion Criteria:

  • Severe liver or renal disease (creatinine > 100 μmol/L, ASAT/ALAT > 2* ULN, alkaline phosphatase > 2 * ULN)
  • History of heart disease, signs of cardiac failure or abnormal ECG
  • Present or previous malignancy
  • Pregnancy or failure of fertile female to comply with contraceptional planning, or breast-feeding. (Safe contraceptive methods include birth control pills, IUD, and gestagen implants) . Plans of pregnancy within 2 years.
  • Participation in other clinical intervention studies
  • Anti-inflammatory therapy (except aspirin £ 100 mg/d)
  • Active infections (CRP>30), history of recurrent infection or predisposition to infections
  • Neutropenia: ANC < 1.5*109/L, or anaemia: Haemoglobin < 8.0 g/dL
  • Immune-suppressive treatment or immune-deficiency
  • Presence at diagnosis of late diabetic complications
  • Concurrent vaccination with live vaccine. Known need for live vaccinations within 2 years.
  • Use of Etanercept within 6 months before screening or during the double-blinded study period
  • Hypersensitivity to E. coli-derived proteins, anakinra or any components of the product.
Both
18 Years to 35 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark,   Spain,   Germany,   Netherlands,   Poland,   Italy,   Switzerland
 
NCT00711503
2007-007146-34, EudraCT 2007-007146-34, Danish EthicalH-D-2008-060, Danish Datatilsyn2007-41-1652, JDRF file no. 17-2007-1804
Yes
Lise Tarnow, Steno Diabetes Center
Steno Diabetes Center
  • Juvenile Diabetes Research Foundation
  • Oeresund Diabetes Academy
Principal Investigator: Thomas R Mandrup-Poulsen, MD, DMSc Steno Diabetes Center
Study Director: Marc Donath Universtity of Zürich
Study Director: Flemming Pociot, DMSc Steno Diabetes Center
Study Director: Charles Dinarello University of Colorado Health Science Center
Study Chair: Edwin Gale, Professor Bristol University, UK
Steno Diabetes Center
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP